Illustrative image.
Ryeqo
Estradiol Hemihydrate
$696.00
40/1/0.5 mg · 84 tablets · 3 months supply
BrandBranded medicine
$232.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$2784a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
40/1/0.5 mg
FDA boxed warning
BOXED WARNING
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than “synthetic” estrogens at equivalent estrogen doses (See
WARNINGS, Malignant neoplasms, Endometrial cancer ).
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease (See
WARNINGS, Cardiovascular disorders ).
The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (See
CLINICAL PHARMACOLOGY, Clinical Studies ).
The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy (See
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Safety information
FDA boxed warning
BOXED WARNING
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than “synthetic” estrogens at equivalent estrogen doses (See
WARNINGS, Malignant neoplasms, Endometrial cancer ).
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease (See
WARNINGS, Cardiovascular disorders ).
The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (See
CLINICAL PHARMACOLOGY, Clinical Studies ).
The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy (See
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The supplied estradiol tablet label says it should not be used in people with: • Unexplained abnormal genital bleeding. • Known, suspected or previous breast cancer, except in selected patients being treated for breast cancer that has spread. • Known or suspected tumours whose growth depends on estrogen. • A current or previous blood clot in a deep vein or the lungs. • Current or recent disease caused by a clot in an artery, such as a stroke or heart attack, including within the past year. • Liver disease or impaired liver function. • A known allergy to any tablet ingredient. • Known or suspected pregnancy. This extract does not provide separate conditions requiring caution.
Interactions
Tell your doctor if you take thyroid hormone replacement, as estradiol may increase the amount of thyroid hormone treatment you need. Estradiol can affect blood test results, including tests of blood clotting, thyroid hormones and other hormone-binding proteins. It may also increase HDL cholesterol and triglycerides, lower LDL cholesterol and impair glucose tolerance. It can reduce the response to a metyrapone test, so tell the clinician arranging this test that you take estradiol.
Using Ryeqo
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Detailed information for this medicine is being written by our pharmacy team. Pack sizes and pricing are shown alongside.
Clinical information on this page is summarised from the US FDA label ESTRADIOL TABLET [A-S MEDICATION SOLUTIONS] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Osphena
Ospemifene
Tablets · from 30 per pack
Also for women's health
Brand $99.00
Danocrine
Danazol
By Sanofi
Tablets · from 60 per pack
Also for women's health
Generic $138.00
Vagiflora
dfg
By Assos
Capsules · from 14 per pack
Also for women's health
Generic $49.00
Rafael Bountiful Milk
Chalav Rav
By Rafael
Bottle · from 1 per pack
Also for women's health
Brand $19.00